Novartis Cyclosporine Sales Advance 12% To $637 Mil. At Half-Year Mark

Despite the advent of generic competition in the U.S., sales of Novartis' Sandimmun/Neoral cyclosporine franchise advanced 12% in local currencies in the first six months of 1999.